Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California; Department of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California.
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):408-417. doi: 10.1016/j.ijrobp.2017.09.038. Epub 2017 Sep 28.
Definitive treatment of nasopharyngeal carcinoma (NPC) is challenging owing to its rarity, complicated regional anatomy, and the intensity of therapy. In contrast to other head and neck cancers, the effect of facility volume has not been well described for NPC.
The National Cancer Database was queried for patients with stage II-IVB NPC diagnosed from 2004 to 2014 and treated with definitive radiation. Patients with incomplete staging, unknown receipt or timing of treatment, unknown follow-up duration, incomplete socioeconomic information, or treatment outside the reporting facility were excluded. High-volume facilities (HVFs) were defined as the top 5% of facilities according to the annual facility volume.
The present analysis included 3941 NPC patients treated at 804 facilities with a median follow-up duration of 59.4 months, including 1025 patients (26.0%) treated at HVFs. Treatment at HVFs was associated with significantly improved overall survival (OS) on multivariable analysis (hazard ratio 0.79, 95% confidence interval 0.69-0.90; P=.001). In propensity score-matched cohorts, 5-year OS was 69.1% versus 63.3% at HVFs versus lower volume facilities (LVFs), respectively (P=.003). Similar results were seen when facility volume was analyzed as a continuous variable. The effect of facility volume on survival varied by academic status (P=.002 for interaction). At academic centers, the propensity score-matched cohorts had 5-year OS of 71.4% compared with 62.4% (P<.001) at HVFs and LVFs, respectively. In contrast, the 5-year OS was 63.5% versus 67.9% (P=.68) in propensity score-matched patients at nonacademic HVFs and LVFs.
Treatment at HVFs was associated with improved OS for patients with NPC, with the effect exclusively seen at academic centers.
由于鼻咽癌(NPC)罕见、区域性解剖结构复杂以及治疗强度大,因此其确定性治疗极具挑战性。与其他头颈部癌症不同,NPC 对治疗机构容量的影响尚未得到很好的描述。
本研究通过国家癌症数据库(National Cancer Database),对 2004 年至 2014 年间诊断为 II-IVB 期 NPC 并接受根治性放疗的患者进行了查询。排除了分期不完整、治疗情况未知、随访时间未知、社会经济信息不完整或治疗不在报告机构的患者。高容量机构(HVF)定义为根据机构年度容量排名前 5%的机构。
本分析纳入了 804 家机构治疗的 3941 例 NPC 患者,中位随访时间为 59.4 个月,其中 1025 例(26.0%)患者在 HVF 接受治疗。多变量分析显示,在 HVF 接受治疗与总体生存(OS)显著改善相关(风险比 0.79,95%置信区间 0.69-0.90;P=.001)。在倾向评分匹配队列中,5 年 OS 分别为 HVF 组和低容量机构(LVF)组的 69.1%和 63.3%(P=.003)。当将机构容量作为连续变量进行分析时,也得到了相似的结果。机构容量对生存的影响因学术地位而异(交互作用 P=.002)。在学术中心,倾向评分匹配队列的 5 年 OS 分别为 71.4%、62.4%(P<.001),而 HVF 和 LVF 组分别为 62.4%和 71.4%。相比之下,在非学术性 HVF 和 LVF 中,倾向评分匹配患者的 5 年 OS 分别为 63.5%和 67.9%(P=.68)。
在 NPC 患者中,在 HVF 接受治疗与 OS 改善相关,其效果仅在学术中心显现。